Skip to main content

Improving Genome Editing Efficiency (IMGENE)

Objective

CRISPR genome editing technology is considered to become the greatest technological improvement in biomedical research since the invention of the polymerase chain reaction 25 years ago and pharmaceutical companies as well as academic research are eager to apply it. However, the efficiency of introducing defined changes into the genome by CRISPR is still low, currently limiting its application in basic research, industry and gene therapy. IMGENE unites expert European research groups of academia and industry to address by innovative and complementary approaches the low efficiency of precise genome editing using CRISPR technology. To our best knowledge, IMGENE is the only concerted approach to tackle the important problem of low genome editing efficiency of CRISPR in a multidisciplinary, intersectorial manner. The IMGENE consortium consisting of 6 academic and 1 industrial beneficiary (AstraZeneca), 2 industrial partners (Taconic; MilliporeSigma), and the patient organization Genetic Alliance, aims to improve the genome editing efficiency of CRISPR by research training of 8 ESRs to unleash the full potential of this technology. Combining complementary knowledge on protein chemistry, molecular biology, cellular biology, viral vectors, transgenic mice, gene therapy, and bioinformatics present in the network, IMGENE will establish novel tools and protocols for improved CRISPR genome editing efficiency that will be of immediate benefit for health and life science research, the pharmaceutical industry, and the application of gene therapy. In addition, IMGENE addresses crucial ethical questions related to the application of genome editing technology in animals, plants, and humans, which have to be solved to gain acceptance by the society. By excellent research training of 8 ESRs on a scientifically and economically highly relevant topic and additional training in transferable skills, IMGENE will educate novel leaders with great career perspectives in industry and academia.

Call for proposal

H2020-MSCA-ITN-2017
See other projects for this call

Coordinator

KOBENHAVNS UNIVERSITET
Address
Norregade 10
1165 Kobenhavn
Denmark
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 580 163,76

Participants (6)

ASTRAZENECA AB
Sweden
EU contribution
€ 263 659,32
Address
Vastra Maelarhamnen
151 85 Sodertaelje
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
UNIVERSITAETSKLINIKUM FREIBURG
Germany
EU contribution
€ 249 216,48
Address
Hugstetter Strasse 49
79106 Freiburg
Activity type
Higher or Secondary Education Establishments
INSTITUTO DE BIOLOGIA MOLECULAR E CELULAR-IBMC
Portugal
EU contribution
€ 238 356,36
Address
Rua Alfredo Allen 208
4200 135 Porto
Activity type
Research Organisations
ACADEMISCH ZIEKENHUIS LEIDEN
Netherlands
EU contribution
€ 255 374,28
Address
Albinusdreef 2
2333 ZA Leiden
Activity type
Higher or Secondary Education Establishments
MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (MDC)
Germany
EU contribution
€ 249 216,48
Address
Robert Rossle Strasse 10
13125 Berlin
Activity type
Research Organisations
USTAV MOLEKULARNI GENETIKY AKADEMIE VED CESKE REPUBLIKY VEREJNA VYZKUMNA INSTITUCE
Czechia
EU contribution
€ 232 422,48
Address
Videnska 1083
142 20 Praha 4
Activity type
Research Organisations

Partners (3)

Taconic GmbH
Germany
Address

Cologne
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Millipore Sigma
United States
Address

Massachusetts
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
GENETIC ALLIANCE UK LTD
United Kingdom
Address
Unit 4D Leroy House , Essex Road 436
N1 3QP London
Activity type
Other